Aprogen Inc. Overview
Aprogen Inc. is a loss-making Korean biopharmaceutical holding company. It sits on top of a 55-year-old listed industrial shell, the former KIC, and its strategy rests on one technological claim: perfusion (continuous) cell-culture manufacturing at the Osong plant can produce monoclonal antibodies at a fraction of the cost of fed-batch competitors. Its lead asset is AP063, a trastuzumab (Herceptin) biosimilar. In 2026 both the EMA and the FDA indicated that AP063 could proceed toward approval without a confirmatory Phase 3, which shifts the critical path to process-validation (PPQ) manufacturing and dossier filing. Behind AP063 sit adalimumab and rituximab biosimilars, an osteoarthritis biologic (AP209), an in-licensed anti-VISTA immuno-oncology antibody (PMC-309) and, through listed subsidiary Apton, the Phase 2-complete mobiliser burixafor (GPC-100). Consolidated revenue (KRW 118bn in FY2025) still leans heavily on non-pharma businesses: hardfacing, semiconductor-equipment parts, geothermal engineering and insulation. The group depends on repeated intra-group equity and convertible-bond financing.
What the company does
Aprogen operates at two levels.
Parent level. The listed entity is a bio R&D company and, since January 2025, a statutory holding company. It owns and directs the group's biologics pipeline: biosimilars and novel antibodies or fusion proteins. It also retains legacy KIC industrial activities, chiefly hardfacing (wear-resistant overlay cladding) and insulation for heavy-industry plant [S4][S38].
Group level. Consolidated revenue includes several listed and unlisted subsidiaries:
Aprogen Biologics: (KOSPI: 003060; 56.9% owned): pharmaceutical sales, Osong plant CMO/CDMO, and semiconductor-equipment parts through its control of N2Tech.
Aptochrome: (formerly AP Healthcare; 71.7%): pharmaceutical distribution.
Apton: (KOSDAQ: 270520; formerly GeoLit Energy, then Apt Neuroscience; 31.6%): geothermal/renewable-energy engineering plus new-drug development.
KIC Industrial Machinery (Zhangjiagang) Co: (China; 100%).
[S2][S27][S33]
Company's own description
The June 2025 IR presentation describes the company as a biotech that develops commercially attractive biologics on the strength of world-class technology. Its stated main business is the development, manufacture and sale of biosimilars and novel biologics (bispecific antibodies and dual-receptor fusions). It highlights:
-
its 2020 designation as Korea's first bio "unicorn";
-
a claimed lowest-in-world manufacturing cost; and
-
a proprietary, internationally registered bispecific-antibody platform.
[S3]
In November 2025 management restated strategy as three pillars: biosimilars (exploiting regulatory easing), innovative new drugs (immuno-oncology and osteoarthritis), and "hybrid" CMO. [S31]
Business and revenue model
| Revenue stream | Model | Status (Oct 2026) | Source |
|---|---|---|---|
| Biosimilar licensing / commercial supply | Licensing of sales rights to regional distributors plus supply from Osong. The company targets about a 50% price discount versus competitors. | Pre-revenue for AP063, AP096 and AP056. Infliximab biosimilar GS071 is approved in Japan (2017); its current commercial contribution is not disclosed. | [S3][S19] |
| Novel drugs | Early licence-out (L/O) or co-development with global pharma | AP209 is entering Phase 1; PMC-309 is in Phase 1a/1b (Australia); GPC-100 (via Apton) is planning Phase 3 | [S3][S29][S34] |
| CMO / CDMO | Fee-for-service drug substance and drug product manufacturing at Osong | The plant was approved by Korea's Ministry of Food and Drug Safety (MFDS) as a specialised biologics CMO in June 2024. One molecule was won (DS+DP) and three were under negotiation as of mid-2025. | [S3][S25] |
| Pharmaceutical sales / distribution | Trading margin | Revenue-generating (43% of the 2Q26 mix with all pharma combined) | [S4] |
| Hardfacing | Industrial service/product (legacy KIC) | Revenue-generating (23% of mix) | [S4] |
| Semiconductor-equipment parts | Manufacturing (N2Tech) | Revenue-generating (22% of mix) | [S4][S27] |
| Renewable energy (geothermal) | Engineering (Apton) | Revenue-generating (10% of mix) | [S4][S34] |
| Insulation | Industrial (legacy KIC; LNG/plant) | Revenue-generating (3% of mix) | [S4] |
Product versus service versus licensing mix: on the 2Q26 mix, roughly 43% is pharmaceutical (mostly product and distribution sales) and about 58% is industrial product or engineering revenue. The rows sum to 101% because of source rounding. Licensing revenue is not separately disclosed and appears immaterial.
Value-chain position, customers and end-markets
| Area | Customers / end-markets |
|---|---|
| Biosimilar partners | Regional pharmaceutical distributors (Europe, US) |
| CDMO clients | Biopharma sponsors, including European companies and group affiliates (e.g. Apton's Parkinson's programme) |
| Therapeutic areas | Oncology (HER2+ breast cancer, haematological malignancy), autoimmune/inflammatory disease, osteoarthritis, neurodegeneration |
| Industrial customers | Steel, petrochemical, shipbuilding, power-generation and LNG plant operators (KIC heritage) |
| Semiconductor customers | Semiconductor-equipment supply chain (N2Tech) |
In biologics, Aprogen is vertically integrated from cell-line development through drug substance and drug product. Its stated strength is the upstream step, where it combines high-titre cell lines with perfusion culture. It relies on partners for clinical execution (e.g. Syneos as CRO for the AP063 Phase 3) and for commercial distribution [S3][S19].
[S25][S38]
Independent characterisation
Aprogen is best understood as a high-burn, pre-commercial biosimilar platform bolted onto a listed industrial shell. It is surrounded by a web of listed affiliates whose capital raises circulate within the group.
The economic thesis is real and specific. Perfusion at 2,000L working volume is claimed to yield 92–200 kg of antibody per batch, against roughly 30–60 kg for a 12,000–15,000L fed-batch run. If that holds at commercial scale under cGMP, it supports aggressive price-led entry into mature biosimilar molecules.
The execution record is weak, however:
-
no Western approvals after more than two decades;
-
operating losses of KRW 87–119bn every year from FY2021 to FY2025;
-
market value down well over 90% from 2022 levels; and
-
persistent press scrutiny of related-party funding loops.
[S1][S3][S27][S35]
Strategy
Stated corporate strategy (paraphrased from the June 2025 IR deck and November 2025 statement)
The vision is to become a company with world-class commercial competitiveness from R&D through manufacturing, on four tracks:
-
Accelerate biosimilar development and approval.
-
Co-develop or out-license novel drug projects.
-
Open global distribution channels for commercialisation.
-
Push the CDMO business in earnest.
[S3]
Within this, management frames "three engines" (CDMO, biosimilar rights licensing, novel drugs) and 13 concurrent projects: 6 CDMO, 3 licensing and 4 novel-drug projects. The deck aspires to a "Global Top Tier for CDMO" and indicates an expected turnaround around 2027 [S3].
The November 2025 restatement narrowed this to biosimilars (leveraging FDA/EMA streamlining), innovative drugs (PMC-309, AP209) and hybrid CMO [S31].
Strategic initiatives (last 24 months)
| Date | Initiative | Detail | Source |
|---|---|---|---|
| Oct–Nov 2024 | FDA Type 2 BPD meeting on AP063 PPQ | Sought acceptance of a reduced PPQ data package using the sub-batch approach | [S20] |
| Dec 2024 – Jan 2025 | Neurodegeneration entry via GeoLit Energy (now Apton) | 17.22% stake; Parkinson's patents (KRW 5.4bn); plan to reach at least 36.3% via a KRW 45bn CB | [S24] |
| 1 Jan 2025 | Holding-company conversion | Fair Trade Act holding-company structure | [S7] |
| Mar 2025 | Diversification into semiconductor parts | Aprogen Biologics buys the Montana Fund No. 72 vehicle controlling N2Tech | [S26][S27] |
| Jun 2025 | Crypto-asset strategy at Apt Neuroscience | US subsidiary Aptelos to invest in digital assets | [S43] |
| Aug 2025 | Immuno-oncology in-licensing | PMC-309 from PharmAbcine | [S29] |
| Aug 2025 | Consolidated AP Healthcare control | Stake raised to 71.66% | [S28] |
| Nov 2025 | AP063 clinical strategy reset | Phase 3 replaced by quality and PK-centric package; about KRW 130bn savings claimed | [S20] |
| Feb 2026 | Balance-sheet clean-up at subsidiaries | 15:1 (Aprogen Biologics) and 20:1 (Aptochrome) capital reductions to offset deficits | [S8] |
| May 2026 | Regulatory de-risking of AP063 | EMA and FDA alignment on no Phase 3 | [S21][S22] |
| Mid-2026 | AP209 first-in-human | MFDS approval for a 46-patient study; IRB at Kyung Hee University Hospital | [S37] |
| Jul–Sep 2026 | Cell-therapy booster and obesity | Apton's KRW 10bn into GPCR; global rights to GPC-100; Aprogen clinical team assembled to run Phase 3 | [S33][S34] |
ESG and sustainability commitments: none disclosed.
Cost programmes: the only explicit programme is the 2022–2023 emergency management and voluntary retirement scheme [S13]. No quantified cost targets were identified.
Medium-term targets and guidance
The company has issued no formal financial guidance.
Historic aspirational statements have not been met. In 2020, group materials projected biosimilar revenue surpassing KRW 1 trillion by 2026, whereas actual FY2025 revenue was KRW 118bn [S9][S1]. In January 2024 the company cited an internal valuation of KRW 2.6tn, versus a market capitalisation of roughly KRW 0.05–0.07tn in 2026 [S15][S4].
Pipeline timing statements:
-
AP096: trials to 2027 and launch as early as 2028, under the 2024 co-funding plan [S18].
-
GPC-100: Phase 3 results targeted within about 2 years of start [S34].
-
AP063: BLA to follow completion of PPQ data; no date given [S21].
Products & Services
Biosimilars (Pharmaceuticals / R&D)
| Product | Reference product (molecule) | Indications | Stage (latest verified) | Target customer | Key specifications / capabilities | Pricing model | Source |
|---|---|---|---|---|---|---|---|
| AP063 | Herceptin (trastuzumab) | HER2+ early and metastatic breast cancer | US Phase 1 completed (2019–20). Global Phase 3 (APRILIAH, 720 patients) launched 2023 and ended early in April 2025. EMA Scientific Advice and an FDA pre-BLA meeting (May 2026) indicate approval can be pursued on analytical plus PK/immunogenicity data without Phase 3. Next step: PPQ manufacturing, then BLA/MAA. | Oncology payers and hospitals in EU/US via distribution partners | 92 kg per 2,000L perfusion batch; 8 batches/yr gives 736 kg/yr, which the company equates to about 40% of world consumption. FDA/EMA previously accepted each of 6 purification sub-batches as an independent DS batch. | Not disclosed; strategy is deep discount (target about 50% below competitors) | [S3][S19][S20][S21][S22][S23] |
| AP096 | Humira (adalimumab) | Rheumatoid arthritis, Crohn's disease and other autoimmune conditions | Clinical material produced (Nov 2024 run harvested 201.5 kg in one perfusion run); clinical programme in preparation. A 2024 plan targeted trials to 2027 and launch as early as 2028. | Autoimmune market via partners | 156 kg/batch, 8 batches/yr, 1,248 kg/yr; the company claims this exceeds 100% of world consumption | Not disclosed. AP Healthcare co-funds KRW 70bn in return for a share of commercial proceeds. | [S3][S18] |
| AP056 | Rituxan (rituximab) | Non-Hodgkin lymphoma, CLL, autoimmune disease | Clinical material production. The IR deck says "preparing" on one slide and "completed" on another (inconsistent). | Oncology / autoimmune | 102 kg/batch, 7 batches/yr, 714 kg/yr (about 34% of world consumption claimed) | — | [S3] |
| GS071 | Remicade (infliximab) | Autoimmune / inflammatory disease | Approved in Japan (2017). US Phase 3 completed (2019–20). Commercial batch production from 2021. A global sales-rights contract was signed in 2014; counterparty not stated in the sources reviewed. Current sales contribution not publicly disclosed. | Japanese market (via licensee) | — | — | [S3] |
| Avastin (bevacizumab) biosimilar | Avastin | Oncology | Listed in 2021 pipeline communications; current status not disclosed in 2025 materials | — | — | — | [S41] |
Novel biologics (Pharmaceuticals / R&D)
| Asset | Modality | Indication | Stage | Notes | Source |
|---|---|---|---|---|---|
| AP209 | Dual-receptor Fc fusion per the IR deck; described elsewhere as a bispecific antibody (inconsistent descriptions) | Osteoarthritis | Non-clinical toxicology completed. MFDS clinical approval obtained in mid-2026 (46 patients). IRB submission to Kyung Hee University Hospital around August 2026. | Licence-out or co-development discussions with global pharma reported | [S3][S31][S37] |
| PMC-309 | Anti-VISTA monoclonal antibody (immune checkpoint) | Advanced/metastatic solid tumours | Phase 1a/1b in Australia (67-patient target; study end expected 30 May 2028) | In-licensed from PharmAbcine on 18 Aug 2025 (exclusive global R&D, commercialisation and manufacturing rights). Contract value undisclosed but at least 5% of Aprogen's FY2024 revenue. A Keytruda combination is planned. | [S29][S31] |
| Fc-engineered antibody | Fc-enhanced mAb | Triple-negative breast cancer | Preparing non-clinical DS | — | [S3] |
| Bispecific antibody #1 | Bispecific | Acute leukaemia | Cell-line development; animal efficacy shown | — | [S3] |
| Bispecific antibody #2 | Bispecific | Acute leukaemia | Molecule optimisation | — | [S3] |
| ADC antibody | Antibody-drug conjugate | Acute blood cancer | Listed as a licence-out item within the CDMO slide | — | [S3] |
| Bispecific manufacturing platform | Technology | — | Proprietary platform; patents registered in the US and other major countries | Offered as part of CDMO | [S3] |
Apton-held assets (consolidated subsidiary)
| Asset | Description | Stage | Deal terms | Source |
|---|---|---|---|---|
| Burixafor (GPC-100) | Rapid-acting mobiliser that moves haematopoietic stem cells and immune cells into peripheral blood. Reported to raise blood T-cell counts 7–10x or more within about an hour. | US Phase 2 completed (multiple myeloma stem-cell mobilisation). FDA Orphan Drug Designation. Planned single US Phase 3 of about 120 patients, targeting results within about 2 years. Potential expansion to AML, sickle-cell disease and in-vivo CAR-T "booster" use. | Global exclusive rights (26 Aug 2026): KRW 6.5bn to counterparty GPCRT; KRW 0.5bn upfront plus up to KRW 472bn in milestones to originator GPCR | [S33][S34] |
| GPR75 programme | Obesity target; antibody discovery with AbTherx; MTAs with two top-10 pharma companies reported | Discovery | Priority negotiation rights via the GPCR investment | [S33] |
| Parkinson's "Substance K" | Endogenous metabolite and enhancers claimed to protect dopaminergic neurons in PD models; diagnostic patent filed November 2024 | Preclinical | Three patents acquired for KRW 5.4bn from Prof. Chung Jong-kyeong (SNU) | [S3][S24] |
Manufacturing services (CDMO/CMO)
Osong plant: perfusion process with switchable fed-batch; 4 × 2,500L plus 2 × 250L bioreactors; 4 purification lines.
Drug-product capacity per year: 6.4M lyophilised vials, 60M liquid vials, 80M prefilled syringes.
Additional capabilities: auto-injector assembly and secondary packaging.
Positioning and commercial status: pitched as "hybrid" CMO; first commercial award (one molecule, DS+DP) won and three more under negotiation per the June 2025 IR deck.
[S3][S31]
Non-pharma products and services
| Line | Description | Share of mix (H1 2026) | Source |
|---|---|---|---|
| Hardfacing | Wear-resistant overlay/cladding for heavy-industry components (KIC heritage). Product-level detail not disclosed. | 23% | [S4][S38] |
| Semiconductor equipment parts | N2Tech parts manufacturing. Product-level detail not disclosed. | 22% | [S4][S27] |
| Renewable energy | Geothermal heat-pump/energy engineering (Apton) | 10% | [S4][S34] |
| Insulation | Insulation for plant and LNG applications (KIC heritage) | 3% | [S4][S38] |
Financial Narrative
Basis. K-IFRS consolidated, KRW bn. FY2021 is shown on the reverse-acquisition (restated) basis used in DART-derived annual data and the June 2025 IR deck: revenue KRW 26.3bn, operating loss KRW 94.6bn [S1][S3].
Income statement
Sources: FY2021–FY2024 from the IR deck consolidated statements [S3]; FY2025 from the DART annual report [S1][S4].
Margins and growth are analyst calculations from the figures above.
Additional measures:
Revenue CAGR FY2021–FY2025: 45.5%. This is inflated by the restated FY2021 base.
Revenue CAGR FY2022–FY2025: 14.6%.
Revenue CAGR FY2023–FY2025: -11.5%.
-
Osong is a roughly KRW 600bn asset [S3], so D&A is likely material and EBITDA meaningfully less negative than operating income, but no figure is estimated.
-
Investing.com shows trailing-twelve-month EPS of KRW -3,636 on a post-consolidation share basis (Aug 2026) [S6].
Dividends per share: nil throughout FY2021–FY2025. No dividend yield is shown by data providers, consistent with accumulated deficits [S4].
Quarterly trajectory
[S1]
H1 FY2026 versus H1 FY2025:
-
Revenue: KRW 71.8bn versus KRW 50.9bn (+41.1%).
-
Operating loss: KRW 43.0bn versus KRW 46.4bn.
-
Net loss: KRW 70.4bn versus KRW 72.3bn.
Balance sheet
Source: IR deck consolidated statements [S3].
Notes on the balance sheet:
-
The deck's current and non-current asset subtotals do not sum to total assets in FY2023–FY2024. Total assets are shown as reported.
-
Third-party data imply equity was eroded by the FY2025 net loss of KRW 140.6bn, partly offset by capital raises. Valueline shows a price-to-book ratio of 1.11x at a KRW 67bn market cap (Aug 2026) [S5]; Butler shows 0.83–0.91x [S4].
-
Short/long debt split, goodwill and intangibles, working capital (FY2025): not publicly disclosed in retrieved sources.
Total assets at 31 Mar 2025: KRW 643.1bn [S3].
Cash flow
Qualitatively:
Dividends and buybacks: no dividends were paid. Treasury shares are about 5.97% of issued shares [S4], but no buyback programme was identified.
Funding pattern: cash burn of roughly KRW 90–120bn a year at operating level has been funded by repeated rights offerings, third-party placements and CBs placed with affiliates (G-Baise, Apton, Aprogen Biologics, N2Tech-linked funds) [S14][S17][S27][S30][S35].
Ratios
These are analyst calculations on average balances [S3]. The FY2022 ROE is distorted by the negative FY2021 opening equity.
Additional ratio notes:
Third-party ROE: Valueline reports -52.1% (as of 2Q26) [S5]; Butler reports -138.0% (trailing basis) [S4].
Not meaningful: ROIC, net debt/EBITDA and interest coverage, because operating income and EBITDA are negative.
Commentary: trends, inflections and drivers
FY2021 to FY2023: the revenue step-up is consolidation, not organic biosimilar sales. Revenue rose from KRW 26.3bn to KRW 150.6bn. The jump coincides with the July 2022 merger and the 2022 combination of Aprogen Pharmaceuticals with Aprogen Biologics, which brought pharmaceutical sales and the legacy KIC industrial businesses into the consolidated perimeter. Gross margin of about 23–24% in FY2023–FY2024 reflects distribution and industrial products, not biologic pricing.
FY2024 to FY2025: contraction. Revenue fell 21.4% to KRW 118.0bn, with the trough in Q1–Q2 FY2025 (KRW 24–27bn per quarter). The net loss widened to KRW 140.6bn, the worst on the restated series. Aprogen Biologics alone lost KRW 168.3bn net in FY2025 [S40].
FY2026 inflection in the top line only. Q1 and Q2 FY2026 revenue rose 35.8% and 47.0% YoY. The timing matches consolidation of N2Tech's semiconductor-parts business, which accounts for 22% of the mix. Operating losses remain stuck at KRW 20–22bn per quarter, so the cost base (R&D, Osong fixed costs, SG&A) has not been absorbed.
Structural cost. The parent's FY2025 payroll of KRW 15.7bn equals 40.6% of separate-basis revenue of KRW 38.6bn, up from 4.8% in FY2021 [S2]. The Osong plant runs largely for clinical and PPQ batches and small CMO jobs until commercial products arrive.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Structure
| Level | Entity | Ownership | Function | FY2025 total assets (KRW Bn) | FY2025 net income (KRW Bn) |
|---|---|---|---|---|---|
Ultimate controller | G-Baise Co., Ltd. (unlisted; CEO Kang Seon-ju) | 100% owned by Kim Jae-seop per 2020–2022 reporting | Pure holding company, management advisory | — | — |
Listed parent | Aprogen Inc. (007460) | G-Baise 21.8%; related parties 36.63% | Bio R&D, holding company, legacy industrial | 609.9 (FY2024) | -140.6 (consolidated) |
Subsidiary | Aprogen Biologics (003060) | 56.9% | Osong manufacturing/CMO, pharma sales, semiconductor parts (via N2Tech) | 513.6 | -123.0 |
Subsidiary | Aptochrome (formerly AP Healthcare) | 71.7% | Pharmaceutical distribution; co-funder of AP096 | 314.5 | -6.68 |
Subsidiary (de facto control) | Apton (270520; formerly GeoLit Energy / Apt Neuroscience) | 31.6% | Geothermal engineering; Parkinson's programme; GPC-100 | 143.2 | -7.11 |
Subsidiary | KIC Industrial Machinery (Zhangjiagang) Co. | 100% | Legacy industrial (China) | 1.41 | 0.089 |
Grandchild (via Aprogen Biologics) | Montana New Technology Fund No. 72 → N2Tech (227950) | Fund owns 9.65% of N2Tech (largest holder) | Semiconductor-equipment parts | N2Tech: 159.3 (H1 2026) | — |
Grandchildren (at holdco conversion) | Aprogen Pharma, Aprogen I&C, Aprogen Visionary, Vision Bros | — | — | — | — |
Apton subsidiaries | Aptelos Inc. (California; 100% of Apton); GPCR Co. (largest shareholder after KRW 10bn investment) | as stated | Crypto-asset investment (announced 2025); CAR-T booster / GPR75 obesity | — | — |
“—” = not publicly disclosed.
Segment Overview
| Segment | H1FY2026 |
|---|---|
Pharmaceuticals (%) | 43 |
Hardfacing (%) | 23 |
Semiconductor equipment parts (%) | 22 |
Renewable energy (%) | 10 |
Insulation (%) | 3 |
Segment Overview — Pharmaceuticals
| Segment | H1FY2026 |
|---|---|
Pharmaceuticals (KRW Bn) | 30.9 |
Hardfacing (KRW Bn) | 16.5 |
Semiconductor equipment parts (KRW Bn) | 15.8 |
Renewable energy (KRW Bn) | 7.2 |
Insulation (KRW Bn) | 2.2 |
Segment Overview (2)
| Segment | H1FY2026 |
|---|---|
Pharmaceuticals (%) | 62 |
Semiconductors (%) | 33 |
Bio (%) | 3 |
Other (%) | 1 |
Results by Segment
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 56.5 | 65.2 | 87.4 | 67.4 | 73.2 |
Operating income (KRW Bn) | -3.8 | -5.4 | -57.5 | -52.8 | -60.4 |
Net income (KRW Bn) | 9.2 | 5.6 | -115.3 | -105.0 | -168.3 |
Income Statement
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 26.3 | 78.3 | 150.6 | 150.1 | 118.0 |
Gross profit (KRW Bn) | -0.4 | 6.2 | 35.8 | 34.9 | — |
Operating income (KRW Bn) | -94.6 | -119.3 | -88.9 | -86.8 | -95.6 |
Net interest income/(expense) (KRW Bn) | -19.6 | -6.9 | 3.0 | 3.8 | — |
FX and derivative gains/(losses) (KRW Bn) | -0.6 | 2.5 | -0.9 | 4.0 | — |
Pre-tax income (KRW Bn) | -119.3 | -115.6 | -95.2 | -98.7 | — |
Net income (KRW Bn) | -119.2 | -116.1 | -97.3 | -100.4 | -140.6 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | -1.7 | 7.9 | 23.8 | 23.3 | — |
Operating margin (%) | -359.7 | -152.4 | -59.0 | -57.8 | -81.0 |
Net margin (%) | -453.2 | -148.3 | -64.6 | -66.9 | -119.2 |
Revenue growth YoY (%) | — | 197.7 | 92.3 | -0.3 | -21.4 |
Income Statement (Quarterly)
| Metric | Q1FY2024 | Q2FY2024 | Q3FY2024 | Q4FY2024 | Q1FY2025 | Q2FY2025 | Q3FY2025 | Q4FY2025 | Q1FY2026 | Q2FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 38.1 | 35.6 | 36.8 | 39.6 | 26.7 | 24.2 | 35.6 | 31.5 | 36.3 | 35.5 |
Operating income (KRW Bn) | -18.0 | -17.7 | -22.0 | -29.1 | -22.5 | -23.9 | -22.3 | -26.9 | -20.6 | -22.4 |
Net income (KRW Bn) | -18.3 | -18.8 | -21.9 | -41.4 | -30.1 | -42.2 | -33.7 | -34.5 | -28.1 | -42.3 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
Total assets (KRW Bn) | 477.6 | 599.9 | 594.4 | 609.9 |
Current assets (KRW Bn) | 87.2 | 168.5 | 108.5 | 97.1 |
Cash and equivalents (KRW Bn) | 15.9 | 43.1 | 35.7 | 37.1 |
Non-current assets (KRW Bn) | 374.5 | 388.3 | 450.2 | 475.7 |
Total liabilities (KRW Bn) | 478.5 | 138.9 | 176.7 | 169.8 |
Current liabilities (KRW Bn) | 421.9 | 89.9 | 125.6 | 112.9 |
Non-current liabilities (KRW Bn) | 56.5 | 48.9 | 51.1 | 56.9 |
Total equity (KRW Bn) | -0.8 | 461.0 | 417.7 | 440.1 |
Total borrowings (KRW Bn) | 429.7 | 81.0 | 101.0 | 100.3 |
Net debt (KRW Bn) | 413.8 | 37.9 | 65.3 | 63.1 |
Net debt to equity (%) | — | 8.2 | 15.6 | 14.3 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansReturns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
ROE (%) | -50.5 | -22.1 | -23.4 |
ROA (%) | -21.5 | -16.3 | -16.7 |
Current ratio (x) | 1.87 | 0.86 | 0.86 |
Borrowings to equity (x) | 0.18 | 0.24 | 0.23 |
Liabilities to equity (%) | 30.1 | 42.3 | 38.6 |
Asset turnover (x) | 0.15 | 0.25 | 0.25 |
Revenue by Region
| Region | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total consolidated revenue (KRW Bn) | 150.6 | 150.1 | 118.0 |
Data Point Details
| Data point | Value | Date |
|---|---|---|
Share price | KRW 2,015 | ~26 Sep 2026 |
Share price | KRW 2,010 | 17 Sep 2026 |
Share price | KRW 2,365 | 27 Aug 2026 |
Share price | KRW 2,570 | 15 Aug 2026 |
Share price | KRW 2,465 | 2 Jul 2026 |
52-week range (Investing.com) | KRW 280 – 7,800 | Aug 2026 |
Market capitalisation | KRW 50.0–67.0bn | Aug–Oct 2026 |
Shares outstanding | About 21–28M (sources inconsistent) | 2026 |
Capital Markets
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Dividends per share (KRW) | 0 | 0 | 0 | 0 |
Valuation Snapshot
| Multiple | Value | Comment |
|---|---|---|
P/E | Not meaningful (losses) | Valueline -0.80x |
P/B | 0.83–1.11x | Varies by data date |
EV/Sales | About 0.9–1.1x (analyst estimate) | Market cap of about KRW 55–67bn plus FY2024 net debt of KRW 63.1bn, over FY2025 revenue of KRW 118.0bn. |
Capital Markets — Analyst consensus
| Item | Status |
|---|---|
Analyst consensus | 1 broker; target price KRW 1,410 (30–34% below the September 2026 price) |
Dividend policy | No dividends; accumulated deficits |
Buyback authorisation | None identified; treasury shares about 5.97% |
Credit ratings (Moody's, S&P, Fitch) | None; no domestic agency rating identified |
Analyst Conclusions
Management guidance and consensus
Formal financial guidance: none.
Consensus: one broker target of KRW 1,410; no consensus revenue or earnings estimates identified [S4].
Pipeline timing management has signalled: - AP063 BLA after PPQ (no date) [S21].
-
AP096 launch as early as 2028 under the 2024 plan [S18].
-
GPC-100 Phase 3 readout targeted about 2 years after start [S34].
-
Turnaround around 2027 [S3].
Bull case
-
AP063 approval with a structurally lower cost base. The FDA and EMA no-Phase-3 alignment removes the largest development cost [S21][S22]. If perfusion economics hold in PPQ, Aprogen could undercut five or more incumbents profitably in a market worth about USD 2,893/g at reference pricing [S19].
-
Osong as a monetisable asset. A roughly KRW 600bn cGMP plant with 3,000 kg/yr capacity [S3] trades inside a group valued at under KRW 70bn of equity [S4][S5]. A single meaningful CDMO contract, or a licence-out, could re-rate the stock.
-
Late-stage optionality via Apton. An orphan-designated, Phase 2-complete mobiliser with a lean, roughly 120-patient Phase 3 [S34] offers a binary catalyst that is uncorrelated with biosimilars.
Bear case
-
Persistent value destruction. Cumulative net losses of about KRW 574bn from FY2021 to FY2025 (sum of restated figures, [S1][S3]) and no commercial biosimilar revenue in the West after 26 years.
-
Financing circularity and dilution. Capital is recycled among Aprogen, Aprogen Biologics, Apton, N2Tech and G-Baise through CBs, rights issues and loans [S27][S32][S35]. This erodes minority value and creates contagion risk if any node fails.
-
Commoditised targets and execution risk. AP063 enters a trastuzumab market about 84% penetrated by biosimilars [S3] without a named distribution partner. The perfusion sub-batch PPQ approach still faces final regulatory review at BLA [S21].
Catalysts and monitorables (next 12 months)
-
AP063 PPQ completion and BLA/MAA submission dates; any named US or EU commercialisation partner.
-
GPC-100 FDA end-of-Phase-2 meeting outcome and Phase 3 first-patient-in.
-
AP209 first-patient dosing at Kyung Hee University Hospital.
-
Q3 FY2026 report (expected mid-November 2026): whether revenue growth from N2Tech consolidation continues and whether the operating loss narrows below KRW 20bn per quarter.
-
Further CB or rights issues across group companies, CB conversions (overhang), and any capital reduction at the parent.
-
Identity and intentions of Harvest Rose (14.18%).
-
CDMO contract announcements for Osong.
-
Regulatory or exchange actions related to group transactions.
Analyst verdict
Aprogen is two companies stapled together.
The asset with genuine value. Osong and the perfusion process may be one of Korea's more under-appreciated pieces of biologics manufacturing infrastructure. The 2026 regulatory signals on AP063 are the most concrete progress the company has made in years. The FDA and EMA have converged on allowing a trastuzumab biosimilar to proceed on analytical, PK and immunogenicity data alone. In that world the competitive variable is cost of goods, which is exactly the variable Aprogen has optimised for. The single 201.5 kg AP096 harvest is a real data point, not just a slide claim.
The structure that undermines it. The listed parent has lost about KRW 87–119bn at operating level every year since FY2021. More than half of its 2026 revenue now comes from hardfacing, semiconductor parts, geothermal engineering and insulation, businesses unrelated to the thesis. Capital is raised through affiliate-placed CBs and rights issues. Collateral and loans flow between subsidiaries and the founder-owned holding company, and the press has documented this repeatedly. Aspirational targets have consistently missed by an order of magnitude, from KRW 1tn of 2026 revenue promised in 2020 to KRW 118bn delivered in FY2025. Disclosure quality is low: no English reporting, no segment profitability in accessible form, and an unclear share count.
Investment framing. The equity is a deeply discounted, high-volatility option on two binary events: AP063 approval with a credible commercial partner, and GPC-100 Phase 3 progress. It is set against a high probability of continued dilution. On risk-adjusted terms, we would treat it as speculative and sell-side-neutral at best.
What would change the view. Three developments in sequence would warrant reassessment:
-
a signed Western distribution agreement for AP063 with economics disclosed;
-
a third-party CDMO contract of meaningful size; and
-
a visible end to intra-group circular financing.
Until then, the governance discount is likely to persist regardless of scientific progress.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / history | Education | Prior roles |
|---|---|---|---|---|
Kim Jae-seop | Chairman and CEO (representative director). Also co-CEO of Aprogen Biologics and CEO of Apton; inside director of G-Baise. | Founder (2000). Resigned as CEO and director 11 Aug 2021. Re-elected director Nov 2022. Co-CEO from 28 Jul 2023. Sole representative director in the FY2025 business report. | BS, MS and PhD in Microbiology, Seoul National University | Associate Professor, KAIST Biological Sciences; Assistant Professor, SNU Genetic Engineering Research Institute; Research Assistant Professor, University of Wisconsin |
Lee Seung-ho | Former CEO (from Aug 2021); co-CEO with Kim from Jul 2023 | Not listed as representative in the FY2025 filing data reviewed. | — | Head of Nomura investment banking in Korea; formerly Morgan Stanley |
Jin Seok-min | Managing Director; Head, Novel Biologics Research Institute | — | PhD Neurobiology, Ajou University; MS and BS Biology, Kyung Hee University | Chong Kun Dang (neuro team leader); SNU College of Medicine research assistant professor; NIH fellow |
Kim Gyeong-yong | Managing Director; Head, Process Analysis Institute | — | PhD and MS Biochemistry, BS Microbiology, Chungbuk National University | ISU Abxis; LabFrontier |
Kim Mi-suk | Managing Director; Head, Business Management HQ | — | PhD, MS and BS Life Sciences, Sookmyung Women's University | Samsung Medical Center; NIH/NCI; National Cancer Center; Korea Institute of Radiological and Medical Sciences |
Na O-seong | Managing Director; Osong Plant Head (Aprogen Biologics) | — | MS Chemistry, POSTECH; BS Chemistry, Dongguk University | Aprogen Biologics fill-finish head; Hanmi Pharm; Celltrion (culture and fill-finish) |
Kim Jeong-chul | Co-CEO, Aprogen Biologics; affiliate executive and shareholder (0.34%) | — | — | — |
Park Mi-ryeong | Executive; shareholder (2.05%) | — | — | — |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
11 Aug 2021 | Kim Jae-seop resigns as CEO and director; Lee Seung-ho appointed CEO | Intended to professionalise management ahead of an IPO [S11] |
Nov 2022 | Kim Jae-seop re-elected registered director (EGM) | Founder resumes formal board role after the share-price collapse [S11] |
28 Jul 2023 | Kim appointed co-CEO | Cited need for scientific leadership in licensing talks [S11] |
Dec 2024 – Jan 2025 | Kim and Kang Jong-soo appointed to the GeoLit Energy (Apton) board; former Aprogen research head Park Mi-jeong appointed CDO; former broadcaster Choi Woong-ki appointed group PR executive | Control of Apton established [S24] |
Major Shareholders
| Holder | Stake (%) | Basis / date |
|---|---|---|
G-Baise Co., Ltd. | 21.80 | FY2025 business report |
Nexconics Co., Ltd. (related party) | 8.04 | FY2025 |
Kim Jae-seop | 4.05 | FY2025 |
Park Mi-ryeong | 2.05 | FY2025 |
Kim Jeong-chul | 0.34 | FY2025 |
Kang Seon-ju | 0.06 | FY2025 |
Controlling group total | 36.63 (37.66 per Apr 2026 filing) | — |
Harvest Rose | 14.18 | Large-holding report filed 9 Sep 2026. |
National Pension Service | 1.60 | End-2024 |
Treasury shares | about 5.97 | 2026 |
Minority shareholders (49,074 holders) | 57.36 | FY2025 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Overlap | Relative positioning | Source |
|---|---|---|---|---|
Trastuzumab biosimilar | Celltrion (Herzuma) | Direct | Marketed in US and EU for years; scale incumbent | [S3] |
Trastuzumab biosimilar | Samsung Bioepis (Ontruzant) | Direct | Marketed in US and EU | [S3] |
Trastuzumab biosimilar | Amgen (Kanjinti) | Direct | Marketed in US | [S3] |
Trastuzumab biosimilar | Pfizer (Trazimera) | Direct | Marketed in US | [S3] |
Trastuzumab biosimilar | Viatris/Biocon (Ogivri) | Direct | First US trastuzumab biosimilar | [S3] |
Adalimumab biosimilar | Celltrion, Samsung Bioepis, Sandoz, Alvotech, Amgen, Boehringer Ingelheim and others | Direct | Crowded US market since 2023 | — |
Rituximab biosimilar | Celltrion (Truxima), Pfizer (Ruxience), Amgen (Riabni), Sandoz | Direct | Mature | Background knowledge |
CDMO | Lonza (25.6% share, 2023), WuXi Biologics (12.1%), Catalent (10.1%), Samsung Biologics (9.9%), Fujifilm (6.8%), Boehringer Ingelheim (5.9%), AGC Biologics (4.4%) | Direct for antibody DS/DP | Aprogen's share is negligible | [S3] |
Korean perfusion and biosimilar peers | Celltrion (250,000L), Samsung Biologics (604,000L) | Capacity comparison | Aprogen claims 360,000L fed-batch-equivalent output | [S3] |
Stem-cell mobilisers (GPC-100) | Sanofi (plerixafor, Mozobil); BioLineRx (motixafortide) | Direct for multiple myeloma mobilisation | GPC-100 is Phase 2-complete with fast onset claimed | — |
Semiconductor parts / hardfacing / insulation | Fragmented domestic suppliers | Indirect | Not benchmarkable from disclosures | — |
Peer Comparison FY2025
| Metric | Aprogen (FY2025) | Celltrion (FY2024) | Samsung Biologics (FY2024) | Aprogen Biologics (FY2025) |
|---|---|---|---|---|
Revenue (KRW Bn) | 118.0 | about 3,557 | about 4,547 | 73.2 |
Revenue growth (%) | -21.4 | — | — | 8.7 |
Operating margin (%) | -81.0 | about 14 | about 29 | -82.5 |
Recent Developments
Coverage runs from about March 2025 to October 2026.



